IN DATE: 07/07/2003

ETHE TRADEN

PTO/SB/08b(05-03) Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

INFORMATION DISCLOSURE  STATEMENT BY APPLICANT  (Use as many sheets as necessary)  Sheet 02 of 02 Attorney Docket Number 2874-002  NON PATENT LITERATURE DOCUMENTS  Application Number 09/911,904  Filing Date 07/23/2001  First Named Inventor Spencer FARR, et al.  Art Unit 1642  Examiner Name Jeanine Anne Goldberg  NON PATENT LITERATURE DOCUMENTS  aminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, T²	Substitute fo	or form 14	49B/PTO		Complete if Known	$\mathcal{S}_{\lambda}$
xaminer itials*  Cite No.1  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  KRAEMER, et al., Regulation of Prostaglandin Endoperoxide H Synthase-2 Expression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, Volume 330, No. 2, Article No. 0259, Academic Press, Inc.  BARTOSIEWICZ, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.  SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8  O9  FARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Validation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93	EE			Application Number	09/911,904	77
xaminer hitials*  Cite No.1  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  KRAEMER, et al., Regulation of Prostaglandin Endoperoxide H Synthase-2 Expression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, Volume 330, No. 2, Article No. 0259, Academic Press, Inc.  BARTOSIEWICZ, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.  SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8  PARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Valldation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93	INFO	RMA	TION DISCLOSURE	Filing Date	07/23/2001	4
xaminer hitials*  Cite No.1  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  KRAEMER, et al., Regulation of Prostaglandin Endoperoxide H Synthase-2 Expression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, Volume 330, No. 2, Article No. 0259, Academic Press, Inc.  BARTOSIEWICZ, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.  SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8  PARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Valldation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93	STAT	EME	ENT BY APPLICANT	First Named Inventor	Spencer FARR, et al.	0
xaminer clite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposlum, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  KRAEMER, et al., Regulation of Prostaglandin Endoperoxide H Synthase-2 Expression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, Volume 330, No. 2, Article No. 0259, Academic Press, Inc.  BARTOSIEWICZ, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.  SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8  PARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Valldation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93				Art Unit	1642	700
xaminer clite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposlum, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  KRAEMER, et al., Regulation of Prostaglandin Endoperoxide H Synthase-2 Expression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, Volume 330, No. 2, Article No. 0259, Academic Press, Inc.  BARTOSIEWICZ, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.  SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8  PARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Valldation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93		(Use as	many sheets as necessary)	Examiner Name	Jeanine Anne Goldberg	, 9
xaminer hitials*  Cite No.  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  KRAEMER, et al., Regulation of Prostaglandin Endoperoxide H Synthase-2 Expression by 2,3,7,8-Tetrachlorodibenzo-p-clioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, Volume 330, No. 2, Article No. 0259, Academic Press, Inc.  BARTOSIEWICZ, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.  SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8  FARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Validation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93	Sheet	02	of 02	Attorney Docket Number	r 2874-002	22/
xaminer hitials*  Cite No.  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  KRAEMER, et al., Regulation of Prostaglandin Endoperoxide H Synthase-2 Expression by 2,3,7,8-Tetrachlorodibenzo-p-clioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, Volume 330, No. 2, Article No. 0259, Academic Press, Inc.  BARTOSIEWICZ, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.  SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8  FARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Validation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93			MONENATION	LITEDATURE DOOL	Barbaro	· B
itials* No.1 magazine, journal, serial, symposlum, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  KRAEMER, et al., Regulation of Prostaglandin Endoperoxide H Synthase-2 Expression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, Volume 330, No. 2, Article No. 0259, Academic Press, Inc.  BARTOSIEWICZ, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.  SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8  FARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Validation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93		1	NON PATENT	LITERATURE DOCU	MENIS	
2,3,7,8-Tetrachlorodibenzo-p-dioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, Volume 330, No. 2, Article No. 0259, Academic Press, Inc.  BARTOSIEWICZ, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.  SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8  FARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Validation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93			Include name of the author (in CAPITA magazine, journal, serial, symposlu	m, catalog, etc.), date, page	e(s), volume-issue number(s), publisher, city	T <sup>2</sup>
This Technology, Archives of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.  SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8  FARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Validation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93	Or	06	2,3,7,8-Tetrachlorodibenzo-p-dioxir Volume 330, No. 2, Article No. 025	n, Archives of Biochemis 9, Academic Press, Inc.	try and Biophysics, 1996, 319-328,	
Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8  FARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Validation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93	ע	07	This Technology, Archives of Bloch	emistry and Biophysics,	2000, 66-73, Volume 376, No. 1,	
1999, 1-9, Volume 50, Society of Toxicology  MARTON, et al., Drug Target Validation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93		08	Types, Clinical Cancer Research:	An Official Journal of the		
DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11  SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93		09		oxicology		
SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93		10	DNA Microarrays, Nature Medicine	, 1998, 1293-1300, Volu	ıme 4, No. 11	
		11	SCHENA, et al., Parallel Human Genes, Proc. Natl. Acad. Sci. USA,	enome Analysis: Microa , 1996, 10614-10619, Vo	arry-based Expression Montoring of 1000 olume 93	
Hepatoma Cells, Toxicological Sciences, 2000, 399-415, Volume 58, Society of Toxicology	J	12	Burczynski, et al., Toxicogenomics	-Based Discrimination of	f Toxic Mechanism in HepG2 Human	

Examiner Date Canadana U1803					
	Examiner Signature	9 Goldberg	Date Considered	u	18/03

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optionat). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sub	state fo				Co	mplete	if Known	rol nur
ي الم	AT I	or form 1449A/PTO		Application		09/911		
	<i>y</i>	RMATION DISCL	OCUPE	Filing Date		07/23/2		Ų
DEMORT	IFO	RMATION DISCL	USURE		ed Inventor	<del> </del>	er FARR, et al.	,
S	TAT	EMENT BY APP	LICANI	Art Unit		1642	SI I AININ, GLAI.	
				Examiner	Name		e Anne Goldberg	4)
	01	(Use as many sheets as necess	00		Oocket Number	2874-0		
Sheet	01	0	1 02	7,000,00		12017-0		
		<del></del>	U. S. PATEN	IT DOCUMI	ENTS			
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY		me of Patentee or ant of Cited Docur		Pages, Columns, Lines, Relevant Passages or R Figures Appear	
\u		Number-Kind Code <sup>2 (f known)</sup> US- 5,654,401	08/05/1997	Clomo	nts et al.		- igarou i ippoui	
7)~	01	US-	00/00/1997	Cleme	IIIS Et al.			
		US-			re bil padege ist jeli paka hiji nari jiga na hasan sur uur uur uur ee paanaan are			
		US-			art i Merchan en par estructions e de la presencación com presencación			
alformus to are unusualty unit of the North Constitution for		US-		***************************************	**************************************			
		US-		**************************************	- 24 martin artika (da 164 martin	*****		
a të dhe she she d'ann t'on ander menn a		: US-			under de participat de la completación servicido de la completación de			
affections and the management and the m		US-					STORAGE OF AT PART OF THE MENTING THE CONTRACT OF THE STORAGE OF THE STORAGE OF A	4 <del></del>
or, or, or, or great a large specifical measures		US-			na a de la Persona de la compansión de la desidad de la compansión de la desidad de la compansión de la comp			
		US-			g Payang Mag meringganggan daran caga pilant g Pinasi dalah Miri ban Mana			
an consumerous and comment		US-	- 14 Mart of the second		AND THE PERSON NAMED AND THE PERSON OF THE P			
arragani gada a 1862 - 1941 - 1842 - 1845 - 1846 - 1846 - 1846 - 1846 - 1846 - 1846 - 1846 - 1846 - 1846 - 184		US-		AND THE PERSON OF THE PERSON O				
redirects and the military despite specialists of		US-						
		US-						
yangangangan asaga sasi nasawa ili asafiwahi shihi		US-			nagangan néperinganya ji an terbuay ayi makidadi badi 1900 Melaksi 1900 Melaksi 1900 Melaksi 1900 Melaksi 1900	produkan pandengakan pir opa raska second - Manada		
		US-			and the state of t		and the state of t	
And the second s		US-		MANAGEMENT AND RESIDENCE AND R	144(1644)))))) 44444444444444444444444444			
THE STREET WAS THE STREET, MAN AND AND AND AND AND AND AND AND AND A		US.						
			FOREIGN PAT	FNT DOCL	JMENTS			
					<del></del>			
	T						Dames Oct	
Examiner	Cite No.1	Foreign Patent Docu	М	ublication Date M-DD-YYYY	Name of Pa Applicant of Cit		Pages, Columns, Line Where Relevant Pass or Relevant Figures A	ages

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> 'Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>			
CXY	02	WO 00/12760	03/09/2000	Incyte Pharmaceuticals, Inc.	***************************************				
I U	03	WO 99/05320	02/04/1999	Rapigene, Inc.					
	04	EP 0 292 879 A2	11/30/1988	Orion Corporation Ltd.	***************************************				
V	05	WO 01/51667 A2	07/19/2001	integriderm, L.L.C.					
***************************************									

Date Considered Examiner Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection or information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is a large failed by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.